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Methods: Patients admitted to elderly medicine wards at three acute hospitals in England
were recruited to a prospective observational study. Participants were asked to provide a stool
sample as soon as possible after enrolment and then weekly during their hospital stay. Samples
were cultured for C. difficile before ribotyping and toxin detection by PCR. A multivariable lo-
gistic regression model of risk factors for C. difficile colonization was fitted from univariable
risk factors significant at the p < 0.05 level.
Results: 410/727 participants submitted 1 stool sample and 40 (9.8%) carried toxigenic
C. difficile in the first sample taken. Ribotype 106 was identified three times and seven other
ribotypes twice. No ribotype 027 strains were identified. Independent predictors ofearch Building, Brighton and Sussex Medical School, University of Sussex, Falmer, BN1 9PS, United
s.ac.uk (M.J. Llewelyn).
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C. difficile colonization in hospital. 21colonization were previous C. difficile infection (OR 4.53 (95% C.I. 1.33e15.48) and malnutri-
tion (MUST score 2) (OR 3.29 (95% C.I. 1.47e7.35)). Although C. difficile colonised patients
experienced higher 90-day mortality, colonization was not an independent risk for death.
Conclusions: In a non-epidemic setting patients who have previously had CDI and have a MUST
score of 2 are at increased risk of C. difficile colonization and could be targeted for active
surveillance to prevent C. difficile transmission.
ª 2017 The Authors. Published by Elsevier Ltd on behalf of The British Infection Association.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction
Clostridium difficile infection (CDI) is a major infective
cause of nosocomial diarrhoea with symptoms ranging from
mild diarrhoea through to life-threatening colitis and toxic
mega-colon.1 Asymptomatic colonization is more common
than symptomatic disease2 but is laborious to detect by
anaerobic culture and is less infectious than active disease.3
Consequently, diagnostic practice has been to identify only
symptomatic patients using detection of toxins in diarrhoeal
stool for both treatment and infection control purposes.4
With the advent of molecular diagnostics for C. difficile,
identification of carriage is a possibility.
In 2008, guidelines for the prevention of CDI were
introduced in the National Health Service (NHS) of England
and Wales.5 These guidelines targeted a reduction of trans-
mission by symptomatic patients, improved hospital clean-
ing and antimicrobial stewardship. A very marked fall in CDI
cases followed, from a peak in 2007/8 of 55,498 cases to
14,694 in 2012/13.6 However, this decline has now stalled
and in the current endemic transmission situation, symp-
tomatic cases only account for a minority of patient to pa-
tient transmission.7 Whole genome sequencing of C.
difficile isolates from symptomatic CDI cases has shown
that most C. difficile acquisitions arise from a large genet-
ically diverse reservoir rather than on-going transmission of
highly related strains.8 Furthermore, patients who carry
toxigenic strains of C. difficile without disease contribute
to transmission and the burden of symptomatic disease.9
The purpose of our study was to establish how
commonly, in the setting of endemic transmission, hospi-
talised patients carry toxigenic strains of C. difficile in the
absence of diarrhoea and establish whether risk factors for
colonization exist which could be used to target infection
control interventions.Methods
Setting and participants
Participants were recruited from patients admitted to
elderly medicine wards at three large acute NHS hospitals
in England; the Royal Sussex County Hospital Brighton, the
James Cook University Hospital Middlesbrough and the
Bradford Royal Infirmary. Patients were enrolled at Brighton
from July 2012 to Dec 2013 and at Middlesbrough and
Bradford from June 2013 to Dec 2013. At each site
recruitment took place Monday to Friday on 1e4 of the
elderly care wards depending on study nurse availability.Patients were eligible for inclusion if they were aged over 18
years and did not have a diagnosis of C. difficile infection
made by the clinical team according to symptoms and toxin
testing result. Eligible patients were invited to participate
within 24 h of admission to a study ward where possible
but no upper limit was set for time between admission
and enrolment. All eligible patients were invited to partici-
pate if they had capacity to give informed consent or a suit-
able consultee was available to give approval in the case or
patients lacking capacity. Consenting participants were
asked to provide a sample of their first stool after enrolment
and then at weekly intervals during their hospital stay.
Participant demographic and clinical data
Consent was obtained to record data describing participant
demographics, potential risk factors for C. difficile, test re-
sults and outcome (development of symptomatic CDI and
survival) from hospital electronic data, patient notes and
GP records. Whether a patient had a previous history of
toxin-positive C. difficile infection was recorded from the
hospital’s infection control alert system. Diarrhoea was
defined as 3 or more liquid stools (taking the shape of a
container) within a 24 h period up to the time of stool sam-
pling. To assess burden of co-morbid disease a Charlson
score was calculated for each patient.10 As part of routine
clinical care patients were Waterlow (risk of pressure
sores), MUST (risk of malnutrition) and Barthel (activities
of daily living) scored as assessments of frailty.
Sample handling and microbiological analysis
Samples were frozen at 70 C on the day of collection and
stored until tested. For each participant, the first ‘base-
line’ and final stool samples obtained underwent testing for
C. difficile. C. difficile was detected and characterised as
follows. Samples were plated directly onto Brazier’s me-
dium, and incubated anaerobically for two days at 35 C.
In addition, a portion of specimen was heat shocked at
80 C for 10 min, followed by enrichment in cycloserine-
cefoxitin mannitol broth with taurocholate lysozyme
cysteine (CCMB-TAL broth). Broths were incubated anaero-
bically at 35 C for up to 7 days. One millilitre of broth was
centrifuged, the supernatant discarded and the pellet
plated onto Brazier’s medium. After incubation of two
days, suspect colonies were identified as C. difficile by fluo-
rescence under UV light and MALDI-TOF.11 PCR ribotyping
was performed on pure cultured C. difficile isolates. All iso-
lates were also tested by PCR for the presence of tcdA and
tcdB as previously described.12
22 L. Behar et al.Statistical analysis
Normally distributed variables were described by mean and
standard deviation and non-normally distributed variables
were described by median and interquartile range. t-tests
or ManneWhitney U tests were used for comparisons be-
tween groups, where appropriate. Categorical variables
were described by percentages and Chi-squared tests or
Fisher’s exact test were used for comparisons between
groups, as appropriate. All statistical tests were two-
tailed and a p-value of <0.05 was considered significant.
Data from the first stool sample tested for each patient
were used to estimate the prevalence of C. difficile coloni-
zation. Univariable logistic regression models for C. difficile
colonization in each participant’s first stool sample were
fitted for age, gender, previous diagnosis of symptomatic
CDI, admission from residential care, recent hospital admis-
sion (<6 months), Charlson, Waterlow, Barthel and MUST
scores, treatment with antibiotics at admission, proton
pump inhibitor treatment at admission, symptoms of diar-
rhoea and corticosteroids at admission. A multivariable lo-
gistic regression model for C. difficile colonization in each
participant’s first stool sample was then fitted for variables
with p < 0.05 in the univariable analyses.
Ethics
The study was approved by the London e Camden &
Islington research ethics committee (12/LO/0159).
Results
Participants and samples
A total of 727 participants were enrolled in the study from
1782 patients screened at the three participating hospital
sites (Brighton 505/1186, Bradford 116/287 and Middles-
brough 106/309). Four hundred and ten had one or more
stool samples tested for C. difficile (56.4%).Table 1 Baseline characteristics of 727 participants enrolled in
Characteristic No stool sample rece
Male gender 122/316 (38.6%)
Age (median (IQR)) 85.5 (81.4e89.2)
Admitted from residential care 58/314 (18.5%)
Waterlow score (median (IQR)) 14 (11e18)
n Z 261
MUST score (median (IQR)) 0 (0e1)
n Z 266
Barthel score (median (IQR)) 14 (10e19)
n Z 277
Charlson score (median (IQR)) 6 (5e7)
n Z 317
Recent hospital stay (3 months) 116/317 (36.6%)
Previous CDI 10/317 (3.2%)
Proton pump inhibitor prior to admission 135/317 (42.6%)
Antibiotics prior to admission 51/317 (16.1%)
Diarrhoea 29/284 (10.2%)
Bold value signifies p-value <0.05.Demographic and clinical characteristics of tested and
non-tested participants are set out in Table 1. Tested and
untested patients were similar in terms of age, gender-
balance, previous hospital and residential care exposure,
Charlson score, previous CDI and exposure to antibiotic
and proton-pump inhibitors. The functional status of tested
patients was worse (lower Barthel score and higher Water-
low score) and tested patients were more likely to have
diarrhoea.C. difficile colonization
Of 410 patients submitting at least one stool for testing, 40
(9.8%) were carriers of toxigenic C. difficile on testing of
their base-line sample. These comprised a diverse range
of ribotypes with only ribotypes 126 (3) 009, 018, 020,
023, 028, 038 and 039 (all 2) being identified more than
once. No patients carried ribotype 027 strains. Two patients
cultured non-toxigenic C. difficile ribotype 010 and were
excluded from analysis of C. difficile colonization risk
factors.
Of note, first stool samples were taken a median (IQR) of
6 (4e10) days after admission to hospital but time in
hospital before sampling was similar in carriers and non-
carriers (6 days (3e10.5) vs 6 days (4e10) p Z 0.40).
Univariable predictors of C. difficile colonization are shown
in Table 2.
Compared with non-carriers, patients carrying C. difficile
were much more likely to have had a previous diagnosis of
symptomatic C. difficile infection Odds Ratio (OR) 8.48
(95% C.I. 2.77e25.96), to have been a hospital inpatient in
the last 3 months and were more frail as assessed by MUST
and Barthel score. In contrast they were similar in terms of
age, gender, burden of co-morbid disease, and were no
more likely to have been admitted from residential care.
Furthermore, treatment at admission with antibiotics, corti-
costeroids, or proton pump inhibitors were not associated
with C. difficile colonization and carriers were not more
likely to have diarrhoea at admission than non-carriers.the study who did or did not submit at least one stool sample.
ived (n Z 317) Stool sample received (n Z 410) p-Value
159/410 (38.8%) 1.00
86.1 (82.8e89.7) 0.03
81/409 (19.8%) 0.70
16 (12e19)
n Z 399
0.001
0 (0e1)
n Z 390
0.47
13 (8e17)
n Z 402
0.04
6 (5e7)
n Z 409
0.44
159/410 (38.8%) 0.59
14/410 (3.4%) 1.00
199/410 (48.5%) 0.12
68/410 (16.6%) 0.92
87/403 (21.6%) <0.001
Table 2 Univariable risk factors for carriage of C. difficile at baseline sampling.
Characteristic C. difficile carriers
(n Z 40)
Non-carriers
(n Z 310)
Odds ratio 95% C.I. p-Value
Male gender 11/40 (28.9%) 146/370 (39.5%) 0.63 0.30e1.30 0.208
Age, years (median (IQR)) 86.1 (82.3e90.9)
n Z 38
86.1 (82.8e89.8)
n Z 370
1.02 0.97e1.08 0.527
Waterlow score (median (IQR)) 16 (14.0e20.0)
n Z 37
15.5 (12.0e19.0)
n Z 360
1.04 0.98e1.10 0.202
MUST score (2) 15/37 (40.5%)
n Z 37
61/352 (17.3)
n Z 352
3.25 1.60e6.63 0.001
Barthel score (median (IQR)) 10 (6.5e16.5)
n Z 36
13 (8.0e17.0)
n Z 364
0.94 0.89e1.00 0.036
Charlson score (median (IQR)) 5.5 (5.0e7.0)
n Z 40
6 (5.0e7.0)
n Z 369
1.08 0.92e1.27 0.351
Admitted from residential care 8/38 (21.1%) 73/369 (19.8%) 1.08 0.48e2.46 0.852
Recent hospital stay (previous 3 months) 17/35 (48.6%) 87/322 (27.0%) 2.55 1.26e5.17 0.009
Previous CDI 6/38 (15.8%) 8/370 (2%) 8.48 2.77e25.96 <0.001
Proton pump inhibitor prior to admission 18/38 (47.4%) 179/370 (48.4%) 0.96 0.49e1.87 0.906
Corticosteroids prior to admission 2/38 (5.3%) 40/370 (10.8%) 0.46 0.11e1.98 0.295
Antibiotics prior to admission 5/38 (13.2%) 62/370 (16.8%) 0.75 0.28e2.00 0.570
Diarrhoea 9/36 (25.0%) 77/365 (21.1%) 1.25 0.56e2.76 0.587
Bold value signifies p-value <0.05.
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tors of C. difficile colonization were previous C. difficile
infection OR 4.53 (95% C.I. 1.33e15.48) and MUST score
(2) OR 3.22 (95% C.I.1.47e7.06). Recent hospital stay
was border-line significant with an odds ratio of 2.18
(0.99e4.78).
C. difficile acquisition and loss
Two-hundred and fourteen patients had at least two
samples tested. Of 194 who were negative at baseline, 12
(6.2%) acquired C. difficile between their baseline and final
samples. Five patients (1.2%) developed clinically diag-
nosed symptomatic CDI during their hospital stay. Three
were C. difficile carriers and two non-carriers according
to their baseline stool. Of 20 baseline stool C. difficile car-
riers who had a second stool sample, 16 remained positive
and four were negative on repeat testing.
Outcome of C. difficile colonization
The median length of hospital stay for patients submitting
at least one stool sample was 17 (IQR) (11e29) days and was
longer for patients who were C. difficile colonised at base-
line than those who were not (25.5 (13.75e38.0) vs 17
(11e28) days). The all cause 90-day mortality was 89/410Table 3 Multivariable risk factors for C. difficile carriage among
in the univariable analyses).
Characteristic Odds r
Previous CDI 4.53
Recent hospital stay (previous 3 months) 2.18
Barthel score (per point increase) 0.96
MUST score (2) 3.29
Bold value signifies p-value <0.05.(21.7%) and was higher for carriers than non-carriers 15/
40 (37.5%) vs 74/370 (20.0%). However neither outcome re-
mained significant in the multivariable model in which inde-
pendent risk factors for mortality at 90 days were male
gender, prior admission from a residential home, burden
of co-morbid disease by Charlson score and nutritional state
by MUST score (Table 4).
Discussion
We have found a substantial burden of asymptomatic C.
difficile colonization among older hospitalized adults in En-
gland. Furthermore we have identified risk factors for colo-
nization which could be easily applied to identify patients
most likely to be colonized. Such patients, particularly
given that they so often have diarrhoea, are a potential
reservoir for transmission in hospital.9,13 Antigen-
detection and molecular testing approaches now available
allows targeted screening for C. difficile.14 Detection and
isolation of patients carrying C. difficile at hospital admis-
sion through unselected screening has recently been linked
to reduced rates of symptomatic infection.15 We have also
demonstrated that although patients colonized with C.
difficile experience longer hospital stays and greater mor-
tality risk, this effect is not causal. Mortality risk among
these patients is determined by gender, underlying diseaseelderly hospitalised adults (retaining variables with p < 0.05
atio 95% C.I. p-value
1.33e15.48 0.016
0.99e4.78 0.052
0.90e1.03 0.251
1.47e7.35 <0.001
Table 4 Multivariable model risk factors for 90-day survival among elderly hospital admissions with known C. difficile coloni-
zation status (retaining variables with p < 0.05 in the univariable analyses).
Characteristic Odds ratio 95% C.I. p-value
C. difficile colonised 0.61 0.26e1.46 0.27
Male gender 0.46 0.26e0.84 0.01
Hospital stay in last 3 months 0.64 0.35e1.18 0.15
Admitted NOT from own home 0.46 0.24e0.89 0.02
Waterlow (per point higher) 1.02 0.96e1.08 0.6
Charlson (per point higher) 0.84 0.72e0.97 0.02
Barthel (per point lower) 1.04 0.99e1.10 0.12
High risk of malnutrition
(MUST 2)
0.41 0.21e0.81 0.01
Bold value signifies p-value <0.05.
24 L. Behar et al.burden and frailty. This information would be important
when communicating with patients identified as colonized
with C. difficile.
Few similar studies have been performed. Existing data
are predominantly from North America and in the setting of
epidemic ribotype 027 spread. The rate of colonization we
found (9.8%) is comparable with these studies.16e18 Inter-
estingly a recent Swiss study found a much lower preva-
lence of colonization (2%).19 This may reflect differences
in patient and healthcare system factors including anti-
biotic use and is in keeping with the different patterns of
C. difficile infection seen across the world.
While several previous studies have assessed the impact
of C. difficile colonization on risk of subsequent dis-
ease,20,21 and a recent North American study assessed
acquisition and loss of colonization in hospitalised pa-
tients,22 relatively few studies have sought to establish
risk factors for C. difficile colonization among hospital ad-
missions. This is a separate and important question as it ad-
dresses the issue of whether patients bring C. difficile into
hospital with them and could be screened for infection con-
trol purposes. The largest studies to date performed in the
United States23 and Canada24 identified recent hospital
admission, use of corticosteroids, prior CDI and presence
of antibody against toxin B to be associated with coloniza-
tion. Notably prior antibiotic therapy appears to be associ-
ated with disease but not colonization. The epidemiology of
C. difficile in the UK differs from that seen in North America
in several important regards. Epidemic spread of 027
ceased in the UK around 2010 and there is now no dominant
ribotype present.25 Furthermore patients developing CDI in
the UK are typically 15 years older than in North America.
The only non-epidemic UK data we are aware of described
11 patients colonised at admission to hospital in Oxford-
shire.26 That study like ours identified previous hospital
admission as a risk factor but also previous immunosuppres-
sion and surprisingly a protective effect of recent antibiotic
therapy. We have not replicated this finding.
Our study is, as far as we are aware, unique in exploring
the relationship between commonly applied risk scores for
frailty to determine risk of asymptomatic CDI. Frailty may
plausibly influence susceptibility to CDI either through altered
immune responses or intestinal microbiome composition.
Of note previous studies have linked these risk scores to
symptomatic infection. For example, Waterlow pressure
score scale has previously been reported to indicate risk ofsymptomatic CDI.27 Nutritional status predicts hospital length
of stay and mortality in patients with symptomatic CDI and
has been suggested as a screening tool for CDI.28 Decreased
Functional Status has been reported as a Risk Factor for se-
vere CDI elderly people.29
Our study has several significant limitations. Although we
endeavoured to sample prospectively and early in admission
we managed to secure faecal samples from only just over
half the patients and on average patients had already been
in hospital for one week. It is plausible that sampled
patients had a higher rate of C. difficile colonization than
unsampled patients and thus we may have overestimated
carriage. We cannot be certain whether the colonization
we detected was brought into hospital or acquired subse-
quently. Since we did not know the frequency of coloniza-
tion before we started the study we were not able to
carry out a sample size calculation. Our study may be under-
powered and we cannot be certain that our findings are not
subject to type 2 error. Nevertheless this is one of the
largest prospective studies of colonization performed and
the largest we are aware of outside the epidemic setting.
In conclusion, our study indicates that even in a non-
epidemic setting toxigenic C. difficile is commonly carried
by elderly hospitalised patients. Given that overall one fifth
of our patients had diarrhoea, targeted screening and isola-
tion of patients who have previously had CDI, who have
recently been in hospital and who have a MUST score of
2 should be evaluated as a cost-effective intervention to
reduce the burden of symptomatic C. difficile infection in
hospitalized patients.
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